Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. on June 1, 2018, covering events occurring on May 25 and May 26, 2018. The filing details the appointment of Douglas Cesario as Chief Financial Officer (CFO) and Principal Financial and Accounting Officer, replacing Elizabeth Berecz. The company is identified as an emerging growth company.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $250,000 per year.
- Discretionary Bonus: Based on milestones agreed to by the Board or Compensation Committee.
- Severance: Minimum of six months' base salary upon termination without Cause, Death, or Disability. After three years of employment, an additional two months of salary per year of service beyond the initial three years, capped at 12 months total.
- Restricted Stock Award (RSA): 643,501 shares granted on July 23, 2018, vesting 100% on April 23, 2020, or upon a change of control.
- Stock Options: 1,195,073 shares at an exercise price of $0.245 per share. 25% vest on the grant date; the remaining 75% vest monthly over 33 months, or fully upon a change of control.
Material Changes
The primary material change is the leadership transition in the finance function. Elizabeth Berecz resigned as CFO effective May 25, 2018, and Douglas Cesario assumed the role effective May 26, 2018. This change is accompanied by the issuance of unregistered equity securities (RSAs and stock options) to the new CFO under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond standard employment terms. The employment agreement includes restrictive covenants, specifically an indefinite confidentiality and non-solicitation clause. The employment is at-will, subject to termination for Cause, Death, or Disability.
Investor Verification Checklist
- Verify the exact vesting schedule and acceleration triggers for the 643,501 RSAs and 1,195,073 stock options granted to the new CFO.
- Confirm the total dilution impact of the new equity awards on existing shareholders.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Stock Option Agreement (Exhibit 10.2) for specific definitions of "Cause" and "Change of Control."
- Check subsequent filings for any financial performance updates, as this 8-K contains no operational or financial results.